Cargando…
Effective Anti–SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders
BACKGROUND: Mast cells are key players in innate immunity and the T(H)2 adaptive immune response. The latter counterbalances the T(H)1 response, which is critical for antiviral immunity. Clonal mast cell activation disorders (cMCADs, such as mastocytosis and clonal mast cell activation syndrome) are...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8780123/ https://www.ncbi.nlm.nih.gov/pubmed/35074600 http://dx.doi.org/10.1016/j.jaip.2021.12.038 |
_version_ | 1784637754658783232 |
---|---|
author | Rossignol, Julien Ouedrani, Amani Livideanu, Cristina Bulai Barete, Stéphane Terriou, Louis Launay, David Lemal, Richard Greco, Celine Frenzel, Laurent Meni, Cecile Bodemere-Skandalis, Christine Polivka, Laura Collange, Anne-Florence Hachichi, Hassiba Bouzourine, Sonia Messaoud, Djazira Nait Negretto, Mathilde Vendrame, Laurence Jambou, Marguerite Gousseff, Marie Durupt, Stéphane Lega, Jean-Christophe Durand, Jean-Marc Gaudy, Caroline Damaj, Gandhi Gourin, Marie-Pierre Hamidou, Mohamed Bouillet, Laurence Le Mouel, Edwige Maria, Alexandre Zunic, Patricia Cabrera, Quentin Vincent, Denis Lavigne, Christian Riviere, Etienne Gourguechon, Clement Courbebaisse, Marie Lebeaux, David Parfait, Béatrice Friedlander, Gérard Brignier, Anne Lhermitte, Ludovic Molina, Thierry Jo Bruneau, Julie Agopian, Julie Dubreuil, Patrice Ranta, Dana Mania, Alexandre Arock, Michel Staropoli, Isabelle Tournilhac, Olivier Lortholary, Olivier Schwartz, Olivier Chatenoud, Lucienne Hermine, Olivier |
author_facet | Rossignol, Julien Ouedrani, Amani Livideanu, Cristina Bulai Barete, Stéphane Terriou, Louis Launay, David Lemal, Richard Greco, Celine Frenzel, Laurent Meni, Cecile Bodemere-Skandalis, Christine Polivka, Laura Collange, Anne-Florence Hachichi, Hassiba Bouzourine, Sonia Messaoud, Djazira Nait Negretto, Mathilde Vendrame, Laurence Jambou, Marguerite Gousseff, Marie Durupt, Stéphane Lega, Jean-Christophe Durand, Jean-Marc Gaudy, Caroline Damaj, Gandhi Gourin, Marie-Pierre Hamidou, Mohamed Bouillet, Laurence Le Mouel, Edwige Maria, Alexandre Zunic, Patricia Cabrera, Quentin Vincent, Denis Lavigne, Christian Riviere, Etienne Gourguechon, Clement Courbebaisse, Marie Lebeaux, David Parfait, Béatrice Friedlander, Gérard Brignier, Anne Lhermitte, Ludovic Molina, Thierry Jo Bruneau, Julie Agopian, Julie Dubreuil, Patrice Ranta, Dana Mania, Alexandre Arock, Michel Staropoli, Isabelle Tournilhac, Olivier Lortholary, Olivier Schwartz, Olivier Chatenoud, Lucienne Hermine, Olivier |
author_sort | Rossignol, Julien |
collection | PubMed |
description | BACKGROUND: Mast cells are key players in innate immunity and the T(H)2 adaptive immune response. The latter counterbalances the T(H)1 response, which is critical for antiviral immunity. Clonal mast cell activation disorders (cMCADs, such as mastocytosis and clonal mast cell activation syndrome) are characterized by abnormal mast cell accumulation and/or activation. No data on the antiviral immune response in patients with MCADs have been published. OBJECTIVE: To study a comprehensive range of outcomes in patients with cMCAD with PCR- or serologically confirmed coronavirus disease 2019 and to characterize the specific anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immune response in this setting. METHODS: Clinical follow-up and outcome data were collected prospectively over a 12-month period by members of the French Centre de Référence des Mastocytoses rare disease network. Anti–SARS-CoV-2–specific T-cell activity was measured with an ELISA, and humoral responses were evaluated by assaying circulating levels of specific IgG, IgA, and neutralizing antibodies. RESULTS: Overall, 32 patients with cMCAD were evaluated. None required noninvasive or mechanical ventilation. Two patients were admitted to hospital for oxygen and steroid therapy. The SARS-CoV-2–specific immune response was characterized in 21 of the 32 patients. Most had high counts of circulating SARS-CoV-2–specific, IFN-γ–producing T cells and high titers of neutralizing antispike IgGs. The patients frequently showed spontaneous T-cell IFN-γ production in the absence of stimulation; this production was correlated with basal circulating tryptase levels (a marker of the mast cell burden). CONCLUSIONS: Patients with cMCADs might not be at risk of severe coronavirus disease 2019, perhaps due to their spontaneous production of IFN-γ. |
format | Online Article Text |
id | pubmed-8780123 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology |
record_format | MEDLINE/PubMed |
spelling | pubmed-87801232022-01-24 Effective Anti–SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders Rossignol, Julien Ouedrani, Amani Livideanu, Cristina Bulai Barete, Stéphane Terriou, Louis Launay, David Lemal, Richard Greco, Celine Frenzel, Laurent Meni, Cecile Bodemere-Skandalis, Christine Polivka, Laura Collange, Anne-Florence Hachichi, Hassiba Bouzourine, Sonia Messaoud, Djazira Nait Negretto, Mathilde Vendrame, Laurence Jambou, Marguerite Gousseff, Marie Durupt, Stéphane Lega, Jean-Christophe Durand, Jean-Marc Gaudy, Caroline Damaj, Gandhi Gourin, Marie-Pierre Hamidou, Mohamed Bouillet, Laurence Le Mouel, Edwige Maria, Alexandre Zunic, Patricia Cabrera, Quentin Vincent, Denis Lavigne, Christian Riviere, Etienne Gourguechon, Clement Courbebaisse, Marie Lebeaux, David Parfait, Béatrice Friedlander, Gérard Brignier, Anne Lhermitte, Ludovic Molina, Thierry Jo Bruneau, Julie Agopian, Julie Dubreuil, Patrice Ranta, Dana Mania, Alexandre Arock, Michel Staropoli, Isabelle Tournilhac, Olivier Lortholary, Olivier Schwartz, Olivier Chatenoud, Lucienne Hermine, Olivier J Allergy Clin Immunol Pract Original Article BACKGROUND: Mast cells are key players in innate immunity and the T(H)2 adaptive immune response. The latter counterbalances the T(H)1 response, which is critical for antiviral immunity. Clonal mast cell activation disorders (cMCADs, such as mastocytosis and clonal mast cell activation syndrome) are characterized by abnormal mast cell accumulation and/or activation. No data on the antiviral immune response in patients with MCADs have been published. OBJECTIVE: To study a comprehensive range of outcomes in patients with cMCAD with PCR- or serologically confirmed coronavirus disease 2019 and to characterize the specific anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immune response in this setting. METHODS: Clinical follow-up and outcome data were collected prospectively over a 12-month period by members of the French Centre de Référence des Mastocytoses rare disease network. Anti–SARS-CoV-2–specific T-cell activity was measured with an ELISA, and humoral responses were evaluated by assaying circulating levels of specific IgG, IgA, and neutralizing antibodies. RESULTS: Overall, 32 patients with cMCAD were evaluated. None required noninvasive or mechanical ventilation. Two patients were admitted to hospital for oxygen and steroid therapy. The SARS-CoV-2–specific immune response was characterized in 21 of the 32 patients. Most had high counts of circulating SARS-CoV-2–specific, IFN-γ–producing T cells and high titers of neutralizing antispike IgGs. The patients frequently showed spontaneous T-cell IFN-γ production in the absence of stimulation; this production was correlated with basal circulating tryptase levels (a marker of the mast cell burden). CONCLUSIONS: Patients with cMCADs might not be at risk of severe coronavirus disease 2019, perhaps due to their spontaneous production of IFN-γ. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology 2022-05 2022-01-21 /pmc/articles/PMC8780123/ /pubmed/35074600 http://dx.doi.org/10.1016/j.jaip.2021.12.038 Text en © 2022 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Original Article Rossignol, Julien Ouedrani, Amani Livideanu, Cristina Bulai Barete, Stéphane Terriou, Louis Launay, David Lemal, Richard Greco, Celine Frenzel, Laurent Meni, Cecile Bodemere-Skandalis, Christine Polivka, Laura Collange, Anne-Florence Hachichi, Hassiba Bouzourine, Sonia Messaoud, Djazira Nait Negretto, Mathilde Vendrame, Laurence Jambou, Marguerite Gousseff, Marie Durupt, Stéphane Lega, Jean-Christophe Durand, Jean-Marc Gaudy, Caroline Damaj, Gandhi Gourin, Marie-Pierre Hamidou, Mohamed Bouillet, Laurence Le Mouel, Edwige Maria, Alexandre Zunic, Patricia Cabrera, Quentin Vincent, Denis Lavigne, Christian Riviere, Etienne Gourguechon, Clement Courbebaisse, Marie Lebeaux, David Parfait, Béatrice Friedlander, Gérard Brignier, Anne Lhermitte, Ludovic Molina, Thierry Jo Bruneau, Julie Agopian, Julie Dubreuil, Patrice Ranta, Dana Mania, Alexandre Arock, Michel Staropoli, Isabelle Tournilhac, Olivier Lortholary, Olivier Schwartz, Olivier Chatenoud, Lucienne Hermine, Olivier Effective Anti–SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders |
title | Effective Anti–SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders |
title_full | Effective Anti–SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders |
title_fullStr | Effective Anti–SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders |
title_full_unstemmed | Effective Anti–SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders |
title_short | Effective Anti–SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders |
title_sort | effective anti–sars-cov-2 immune response in patients with clonal mast cell disorders |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8780123/ https://www.ncbi.nlm.nih.gov/pubmed/35074600 http://dx.doi.org/10.1016/j.jaip.2021.12.038 |
work_keys_str_mv | AT rossignoljulien effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT ouedraniamani effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT livideanucristinabulai effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT baretestephane effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT terrioulouis effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT launaydavid effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT lemalrichard effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT grecoceline effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT frenzellaurent effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT menicecile effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT bodemereskandalischristine effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT polivkalaura effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT collangeanneflorence effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT hachichihassiba effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT bouzourinesonia effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT messaouddjaziranait effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT negrettomathilde effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT vendramelaurence effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT jamboumarguerite effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT gousseffmarie effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT duruptstephane effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT legajeanchristophe effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT durandjeanmarc effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT gaudycaroline effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT damajgandhi effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT gourinmariepierre effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT hamidoumohamed effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT bouilletlaurence effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT lemoueledwige effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT mariaalexandre effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT zunicpatricia effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT cabreraquentin effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT vincentdenis effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT lavignechristian effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT riviereetienne effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT gourguechonclement effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT courbebaissemarie effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT lebeauxdavid effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT parfaitbeatrice effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT friedlandergerard effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT brignieranne effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT lhermitteludovic effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT molinathierryjo effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT bruneaujulie effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT agopianjulie effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT dubreuilpatrice effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT rantadana effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT maniaalexandre effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT arockmichel effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT staropoliisabelle effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT tournilhacolivier effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT lortholaryolivier effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT schwartzolivier effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT chatenoudlucienne effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders AT hermineolivier effectiveantisarscov2immuneresponseinpatientswithclonalmastcelldisorders |